EU regulator begins review of Pfizer-BioNTech's variant-adapted Covid shot

The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID

Coronavirus vaccines, booster shot
Photo: Bloomberg
Reuters London
2 min read Last Updated : Aug 09 2022 | 4:25 PM IST
The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday.
 
The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe.
 
A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.
 
Last month, the EMA said it had begun a rolling review of another version of the companies' shot which targets the original SARS-CoV-2 strain and Omicron subvariant BA.1.
 
While existing coronavirus vaccines continue to provide good protection against hospitalisation and death, vaccine effectiveness has taken a hit as the virus has evolved.
 
European Union officials plan to use bivalent shots in their autumn vaccination campaign, with most cases in the region now linked to the BA.5 variant.
 
The EMA expects new COVID variant-adapted vaccines to be approved by September, but has signalled it is open to using shots targeting the older BA.1 variant for that campaign, given the shots targeting the newer BA.4 and BA.5 strains are further behind in clinical development.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusOmicronPfizerCoronavirus VaccineEurope

Next Story